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RESEARCH ARTICLE
Assessment of solid microneedle rollers to enhance transmembrane delivery of
doxycycline and inhibition of MMP activity
Abbie Omolua, Maryse Baillyb and Richard M. Daya
aApplied Biomedical Engineering Group, Division of Medicine, University College London, London, UK; bUCL Institute of Ophthalmology,
London, UK
ABSTRACT
Many chronic wounds exhibit high matrix metalloproteinase (MMP) activity that impedes the normal
wound healing process. Intradermal delivery (IDD) of sub-antimicrobial concentrations of doxycycline,
as an MMP inhibitor, could target early stages of chronic wound development and inhibit further
wound progression. To deliver doxycycline intradermally, the skin barrier must be disrupted.
Microneedle rollers offer a minimally invasive technique to penetrate the skin by creating multiple
microchannels that act as temporary conduits for drugs to diffuse through. In this study, an innovative
and facile approach for delivery of doxycycline across Strat-MTM membrane was investigated using
microneedle rollers. The quantity and rate of doxycycline diffusing through the micropores directly cor-
related with increasing microneedle lengths (250, 500 and 750lm). Treatment of Strat-MTM with micro-
needle rollers resulted in a reduction in fibroblast-mediated collagen gel contraction and MMP activity
compared with untreated Strat-MTM. Our results show that treatment of an epidermal mimetic with
microneedle rollers provides sufficient permeabilization for doxycycline diffusion and inhibition of MMP
activity. We conclude that microneedle rollers are a promising, clinically ready tool suitable for delivery
of doxycycline intradermally to treat chronic wounds.
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Introduction
Doxycycline hyclate is a tetracycline compound that is used
as a broad-spectrum antibiotic in the treatment of a wide
variety of bacterial infections including Chlamydia trachomatis
and gonorrhea (Sloan & Scheinfeld, 2008; Kogawa & Salgado,
2012). At sub-antimicrobial doses, doxycycline is also a
broad-spectrum inhibitor of matrix metalloproteinases
(MMPs), endogenous enzymes that play an essential role in
normal wound healing (Manning et al., 2003). MMPs are pro-
duced and secreted by a number of dermal cells including
fibroblasts and are responsible for the digestion of the struc-
tural extracellular matrix (ECM) components, gelatin and col-
lagen. High levels of MMP activity have been widely
documented in the study of the chronic wound microenvir-
onment (Nwomeh et al., 1999; Trengove et al., 1999; Yager &
Nwomeh, 1999; Moor et al., 2009; Widgerow, 2011).
Doxycycline has been experimentally shown to reduce tis-
sue degradation (Bildt et al., 2009; Li et al., 2013) and its
activity as an MMP inhibitor makes it attractive as a potential
treatment for chronic wounds (Naidoo et al., 2009;
Stechmiller et al., 2010). The MMP inhibitory action of doxy-
cycline is independent of its antimicrobial properties and
thus unrelated to its inhibitory effect on bacterial protein
synthesis. Although the full mechanism has yet to be eluci-
dated, it is believed to inhibit enzymatic MMP activity
through the chelation of the zinc molecule and MMP gene
expression (Li et al., 2013). Doxycycline’s inhibitory activity
extends to TNFa-converting enzyme (TACE), a molecule that
causes release of tumor necrosis factor-alpha (TNFa), which is
an important inflammatory mediator known to impair wound
healing (Stechmiller et al., 2010).
The etiopathogenesis of chronic wounds often begins
with MMP-mediated damage occurring below the intact skin
(Wysoci et al., 1993; Saarialho-Kere, 1998). Therefore, as a
potential preventative treatment for chronic wound forma-
tion, doxycycline could be delivered intradermally to suscep-
tible intact skin at the earliest stages of wound development.
Later stages of wound development may also benefit from
the effects of MMP inhibition but are more likely to require
invasive surgical intervention as ultimate treatment.
The primary barrier to intradermal drug delivery (IDD) and
transdermal drug delivery (TDD) is the stratum corneum (SC)
which forms the outermost layer of the epidermis
(Vandervoort & Ludwig, 2008). It is a thin hydrophobic layer
of cells, formed mainly of corneocytes, and has a thickness
that varies from body site to body site – as thin as nine cell
layers on the eyelid and as thick as 50 cell layers on the soles
of the feet (Ya-Xian et al., 1999). This barrier makes thera-
peutic access with IDD to susceptible tissue during the early
stages of chronic wounds challenging.
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To get larger hydrophilic molecules, such as doxycycline
(1.03 kDa), across the skin, the stratum corneum barrier
must be temporarily disrupted. This can be achieved by
using penetration enhancers which chemically or physically
alter the skin to transiently increase its permeability (Pathan
& Setty, 2009). These include skin pretreatments such as hya-
luronidase administration, sonophoresis and iontophoresis
(Williams & Barry, 2004; Benson, 2005). An emerging technol-
ogy indicated in an increasing number of TDD and IDD appli-
cations are microneedles, a form of physical enhancer.
Microneedles come in a variety of designs and delivery
mechanisms depending on the desired application. They can
differ in shaft geometry, tip shape and needle material (Wu
et al., 2008). These physical parameters govern depth of
penetration, rigidity and reusability among other factors.
There are several methods by which microneedles can be
used to deliver a drug through the skin: the ‘poke and patch’
method using solid microneedles, where a drug-loaded patch
is applied onto the micropores (van der Maaden et al., 2012),
the ‘poke and flow’ method, a controlled release method of
infusion through hollow microneedles (van der Maaden
et al., 2012), as well as dissolvable (Kommareddy et al., 2012),
biodegradable (Kim et al., 2012) and coated (Vrdoljak et al.,
2012) microneedles. For single or smaller dosage amounts
such as with vaccines (Kommareddy et al., 2012; Edens et al.,
2013) or insulin (Gupta et al., 2009; Jj et al., 2013), a spot
application with a microneedle patch may be sufficient for
drug delivery. However, to deliver a drug over a larger sur-
face area, such as a region of skin at risk of chronic wound
development, a more efficient microneedling technique for
permeabilizing skin is required. Microneedle rollers offer a
method of achieving barrier disruption over a large surface
area but the ability of this approach to facilitate drug deliv-
ery relevant to chronic wound treatment has not been
explored to date.
Here, for the first time, we demonstrate the feasibility of
using microneedle rollers to facilitate diffusion of doxycycline
across the skin barrier. To simulate intact skin overlying
dermal tissue at risk of developing into a chronic wound, a
dermal tissue equivalent consisting of a free-floating fibro-
blast-populated collagen lattice (FPCL) contraction model
was combined with Strat-MTM membrane, a non-animal-
derived synthetic membrane, to act as a skin barrier mimetic
based on its reported human skin-like permeability properties
(Uchida et al., 2015, Chernokalskaya et al., 2014). The perme-
ation of doxycycline was measured quantitatively using a
Franz diffusion cell under sink conditions and the biological
activity assessed via fibroblast-mediated FPCL compared
between microneedle-treated and untreated Strat-MTM.
Methods
Microneedle rollers
Commercially available CE-marked microneedle rollers were
supplied in three microneedle lengths, 250, 500 and 750 lm
(SodacodaTM, Delmenhorst, Germany). Rollers were composed
of two parts, a detachable head containing the microneedles
and a handle for holding and manual insertion (Figure 1(A)).
Each roller head consisted of 540 titanium microneedles
arranged as nine discs with 60 microneedles each.
Perforation of Strat-MTM by microneedle rollers
Strat-MTM membranes (Merck Millipore, Billerica, MA) were
cut into 23mm circular discs. To perforate the membrane,
the roller was placed onto the membrane and manually
rolled back and forward five times along a single axis. In a
separate experiment to compare perforation by the micro-
needle rollers in a standardized static model, a 500 g weight
(providing a downward force on the microneedles of 3.8 N)
was attached to the roller head before application of the
roller to the membrane for 30 seconds (Figure 1(A)).
Quantification of transmembrane diffusion across
Strat-MTM membranes
Franz diffusion cells
Transmembrane diffusion of doxycycline across Strat-MTM
membranes was measured quantitatively using static Franz
diffusion cells (Soham Scientific, Ely, UK). Cells were of modu-
lar design and consisted of an upper ‘donor’ compartment
and a lower ‘receptor’ compartment. Both chambers had a
bore size of 12mm and could each hold up to 3ml of fluid.
The area of permeation afforded by the cells was 113mm2.
Strat-MTM membranes were cut into discs that overlapped
with the edges of the Franz cell compartments to prevent leak-
age and mounted between donor and receptor chambers with
sealant. Temperature-equilibrated receptor fluid (0.01M PBS)
(NaCl 8mg/ml, Na2HPO4 1.15mg/ml, KH2PO4 0.2mg/ml, KCl
0.2mg/ml; pH 7.4) was sonicated to remove air bubbles and
3ml added to the receptor compartment along with a Teflon-
coated magnetic stirrer (VWR International, Radnor, PA). Cells
were placed in a temperature-regulated water bath on top of a
water-resistant magnetic stirring plate (Thermo Fisher
Scientific, Loughborough, UK) and stirred at 400 rpm to main-
tain receptor solution homogeneity. The water bath was main-
tained at 32 C (human skin surface temperature of limbs).
Conditions for infinite dose permeation were met by using
a concentration of doxycycline hyclate at 10% of its solubility
limit (50mg/ml) deliverable to the receptor compartment.
Doxycycline hyclate solution (10mg/ml) was prepared by dis-
solving 30mg of doxycycline hyclate powder (Alfa Aesar,
Haverhill, MA) in 3ml of PBS (pH 7.4). The solution was
added to the donor compartment. Donor and receptor com-
partments were covered with ParafilmTM (Sigma-Aldrich,
Poole, UK) to prevent water loss through evaporation.
Samples of receptor fluid (200 ll) were collected at 10min
intervals during the first hour, then every hour for the first
five hours, and then at 24 hours. Samples were transferred to
1ml ChromacolTM vials (Thermo Fisher Scientific,
Loughborough, UK), wrapped in foil to protect the solutions
from light and stored at 4 C until high-performance liquid
chromatography (HPLC) analysis was carried out.
Temperature-equilibrated PBS was immediately added back
into the receptor compartment to replace the sample volume
removed and maintain thermodynamic equilibrium.
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High-performance liquid chromatography (HPLC)
An isocratic method for detecting doxycycline hyclate dis-
solved in aqueous solutions was conducted on a modular
HPLC system (Agilent HPLC 1200 series, Agilent Technologies,
Edinburgh, UK) using a 15 cm 4.6 nm, 5 lm, RP-amide col-
umn (Supelco Analytical, Poole, UK). The mobile phase con-
sisted of 75% (v/v) di-iodinated water (with 0.1% [v/v]
trifluoroacetic acid) and 25% (v/v) HPLC-grade acetonitrile
(Sigma-Aldrich). System parameters were set with a pump
flow rate of 1.0ml/min, sample injection volume of 10ml, a
method stop time of 10min and detection wavelength of
273 nm. This method produced a chromatogram with a major
analyte peak corresponding to doxycycline at 6min. A cali-
bration curve was created from serial dilutions of doxycycline
solution. This was used to calculate doxycycline concentra-
tion from solutions of unknown concentration using the area
under the chromatogram peak.
Free-floating fibroblast-populated collagen lattice (FPCL)
assay
Human adult dermal fibroblasts were harvested from a 5mm
punch biopsy excised from the presternal dermis of a healthy
adult donor undergoing blepharoplasty surgery. The biopsy
was mechanically dispersed, outgrown from the explant and
established as a primary in vitro culture (Li et al., 2015).
Monolayer cultures of fibroblasts were grown in T75 cm2
vented flasks in 1 DMEM (Sigma-Aldrich, Poole, UK) supple-
mented with 10% (v/v) FBS (Gibco, Paisley, UK), 1% (v/v)
L-glutamine (Sigma-Aldrich) and 1% (v/v) penicillin–strepto-
mycin–amphotericin B (Sigma-Aldrich). Their environment
was maintained at 37 C and 5% CO2 in a fully humidified
incubator. Cells were used between passages five and 15 and
were grown to 80% confluence before passaging.
Cell monolayers were washed with PBS and detached with
trypsin–EDTA (Sigma-Aldrich). The cells were pelleted by cen-
trifugation at 1500 rpm for 5min and resuspended in FBS.
Concentrated medium was prepared by adding (% volume)
73.7% 10 DMEM (Sigma-Aldrich), 7.4% L-glutamine (Sigma-
Aldrich) and 18.9% sodium bicarbonate (Gibco).
Concentrated medium (160 ll) was added to 1ml of type I
rat tail collagen (First Link UK Ltd., Birmingham, UK) and the
solution neutralized dropwise with 80 ll of 1M sodium
hydroxide (Sigma-Aldrich). 100 ll of 1 105 cells resuspended
in FBS was added to the collagen solution. The cell-enriched
collagen gel solution was cast into 10mm microwells of
uncoated glass bottomed 24-well plates (MatTek Corp.,
Ashland, MA). Gels were polymerized at 37 C for 15–20min
to form the FPCLs.
Fibroblast-mediated FPCL contraction was monitored
using digital photographs of the FPCLs that were taken on
Figure 1. (A) The microneedle roller head, microneedle arrangement and microneedle roller with 500 g mass applied used for static impact insertion of the micro-
needles with a downward force of 3.8 N. (B) SEM image of a single microneedle tip from a 500 lm microneedle roller. (C) SEM images provide a cross-sectional
view of the Strat-MTM membrane, clearly showing its major architectural layers.
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days 1, 3, 6 and 7 with a 16MP camera. The gel area was
measured using the ‘elliptical’ measuring tool in the Java-
based imaging software ImageJVR (National Institutes of
Health [NIH], Bethesda, MD). Contraction was plotted as a
percentage of gel area normalized to the original gel area
when cast on day 0 (also equivalent to microwell area).
Samples of supernatant (75ll) were collected 1 hour after ini-
tial incubation on day 0, and on days 3 and 7, and stored at
20 C for MMP activity measurement.
Mounting Strat-MTM membrane into cell crown inserts
To investigate doxycycline permeation, the Strat-MTM mem-
branes were mounted into cell crowns (Scaffdex, Tampere,
Finland). The cell crowns were inserted into individual wells
of the 24-well MatTek plate so that the basal surface of the
membrane was in contact with the medium (750 ll) bathing
the collagen gels. Treatment solutions (250 ll) containing
doxycycline (416 lM) were pipetted onto the apical surface
of the Strat-MTM membrane. A stock solution of doxycycline
hyclate solution (10mg/ml) was prepared by dissolving
30mg of doxycycline hyclate powder (Alfa Aesar, Haverhill,
MA) in 3ml of PBS (pH 7.4) and adjusted to a final concentra-
tion of 416lM in PBS. Supernatant beneath the mounted
Strat-MTM membrane was sampled from around the collagen
gel on days 0, 3 and 7 using a fine needle and syringe and
stored at 20 C until MMP activity measurements.
MMP activity assay
Total MMP activity was determined using the Abcam FRET-
based MMP activity assay kit according to manufacturer’s
protocol (ab112147; Abcam, Cambridge, UK). Supernatant
(25ll) collected from collagen gel contraction cultures was
transferred to 96-well plates and 25 ll 2mM p-aminophenyl-
mercuric acetate solution added. Plates were incubated at
37 C for 3 hours. MMP red substrate working solution (50 ll)
was added to the samples and the plate incubated at room
temperature for 1 hour, protected from light. Fluorescence
was measured at Ex/Em 540/590 nm using the FLUOstar
Optima plate reader (BMG Labtech, Ortenberg, Germany).
The fluorescent output readings from the MMP activity assays
are relative values that could be affected by signals from
background substances and materials. To correct for this
effect, the readings for each treatment group were normal-
ized to a background control that contained just the treat-
ment solutions (no FPCLs), for each day.
Scanning electron microscopy (SEM)
Membranes, micropores and microneedles were imaged by
SEM. Strat-MTM membranes were air-dried and coated with
gold palladium. Microneedle roller heads were dismantled
before imaging. Samples were mounted onto metal blocks
and placed under vacuum in SEM (XL-30 FEG SEM; Philips
Electron Optics, Eindhoven, The Netherlands). Images were
analyzed in ImageJVR . Micropore area was calculated using
the ‘polygon selections’ tool to outline the perimeter of the
pore and measure the internal area. For each microneedle
length, six micropore areas were calculated.
Optical coherence tomography (OCT)
Microneedles inserted into Strat-MTM membrane by applying
a mass of 500 g were imaged using the Michelson
Diagnostics EX1301 OCT (Michelson Diagnostics, Kent, UK).
The 2D images were analyzed in ImageJVR .
Statistical analyses
A two-way ANOVA with Tukey correction for multiple com-
parisons was carried out to determine statistical significance
of percentage gel contraction and MMP activity between
treatment groups for each day. Where appropriate, results
are expressed as mean± standard error of the mean (SEM)
and in all instances, p< .05 denotes a statistically significant
difference.
Results
Microneedle and Strat-MTM membrane structure
The ultrastructure of the microneedle tips and shafts of the
roller systems were visualized using SEM (Figure 1(B)). Strat-
MTM membrane thickness, measured by analysis of SEM
images, was 300± 2.7lm. Cross-sectional images showed
Strat-MTM had two main architectural layers – a smooth
upper layer that became increasingly porous and had a layer
thickness of 108± 2.8lm, and a thicker highly porous lower
layer composed of bundles of thick synthetic fibers measur-
ing 192 ± 5.8 lm (Figure 1(C)).
Pore formation in Strat-MTM membrane
Maximum contact area with the membrane was nine micro-
needles per row along the x-axis, four microneedles per row
along the y-axis when force was applied perpendicularly and
infinite microneedles along the y-axis when rolled. SEM
allowed the morphology of the micropores created in the
Strat-MTM to be examined in greater detail (Figure 2(A)). Due
to the tip shape of the microneedles, the pores had an atyp-
ical modified diamond shape. Average micropore areas were
11,200 ± 1400, 14,600± 2700 and 17,100 ± 3000 lm2 (static
impact insertion), and 26,800 ± 1400, 29,600 ± 1500 and
36,100 ± 2700 lm2 (manual rolling) for 250, 500 and 750 µm
microneedle lengths, respectively. Although pore size
increased with increasing microneedle length, a statistically
significant difference in micropore area was only observed
between the 250 and 750 lm microneedles for static impact
insertion (p< .001) (Figure 2(B)).
Depth penetration of the roller tips was evaluated using
OCT to assess which skin layer the microneedles would reach.
The tomographic images show that the 500 and 750 lm
length microneedles completely penetrated the 300 lm thick
Strat-MTM (Figure 2(C)). The 750 lm microneedles protruded
further than the 500lm microneedles with a 170 lm tip
DRUG DELIVERY 945
protrusion compared with 80 lm, suggesting that 750 lm
microneedles would reach deeper in full-thickness skin.
The 250lm microneedles were shown to enter the Strat-MTM
but to not fully penetrate the membrane.
Pharmacokinetic profile of doxycycline delivery through
Strat-MTM membrane
The permeation of doxycycline through untreated and micro-
needle-treated Strat-MTM was investigated. Cumulative doxy-
cycline concentration was monitored in the receptor fluid
over 24 hours. No doxycycline was detectable in the receptor
fluid of untreated membranes, indicating that Strat-MTM
alone inhibited doxycycline permeation (Figure 3(A)).
Conversely, doxycycline was detectable in the receptor fluid
in membranes treated with all microneedle lengths after
10min. The lag time (the time taken for the doxycycline to
achieve steady state flux through the membrane) was one
hour across all microneedle lengths. Differences between the
measured cumulative permeated drug concentrations were
statistically significant between all microneedle lengths, with
750lm microneedle-treated membranes having the greatest
rate of drug permeation and 250 lm microneedle-treated
membranes the least. Total doxycycline permeation at
steady state flux was 0.8, 1.6 and 2.2mg/ml and rate of doxy-
cycline permeation during lag time was 0.88, 1.53 and
2.30mg/ml/min for 250, 500 and 750 lm microneedle
lengths, respectively (Figure 3(B)). Dose depletion of doxycyc-
line was exhibited up to 24 hours.
The total theoretical doxycycline concentration deliverable
to the receptor fluid was 5mg/ml (half of that in the
donor fluid), but the maximum concentration reached was
2.2mg/ml when Strat-MTM was permeabilized with the
750lm microneedle rollers. This is possibly due to drug
retention in and on the membrane as indicated by SEM
images and membrane mass measurements. Doxycycline
crystals were observed within the micropores as well as on
the membrane surface after desiccation (Figure 3(C)). Mass
change measurements show that after desiccation there was
a statistically significant increase in membrane mass for both
microneedle-treated and untreated membranes (Figure 3(D)).
Effect of doxycycline on FPCL gel contraction and MMP
activity
FPCLs cultured in FBS-supplemented DMEM contracted over
a seven-day period (Figure 4(A)). FPCLs exhibited a cumula-
tive gel contraction of 60.7 ± 1.6%, 82.4 ± 0.1%, 93.5 ± 0.03%
and 95.2 ± 0.1% on days 1, 3, 6 and 7, respectively (Figure
4(B)). The addition of sub-antimicrobial concentrations of
doxycycline (416 lM) to the culture medium reduced gel con-
traction compared with control groups at equivalent time
points (p< .0001). For this group, gel contraction was
33.8 ± 1.6%, 53.1 ± 0.2%, 56.5 ± 0.4% and 58.5 ± 0.2% on days
1, 3, 6 and 7, respectively (Figure 4(B)). For control FPCLs, the
normalized activity of MMPs was shown to sharply increase
over the seven-day experiment and effectively doubled
between days 0 and 7 (Figure 4(C)). Treatment of the FPCLs
with 416 lM doxycycline significantly inhibited MMP activity
in the gel supernatant compared with control FPCLs on days
3 and 7, maintaining them at day 0 activity levels (p< .0001).
Effect of Strat-MTM on doxycycline delivery to FPCLs
The addition of the Strat-MTM membrane to the cell crown
insert compartmentalized the doxycycline solution from the
FPCLs (Figure 4(D)). This prevented the doxycycline from
reaching the FPCLs to inhibit gel contraction and MMP
Figure 2. (A) SEM image of a micropore [MP] in Strat-MTM membrane after application of a 500 lm microneedle roller. (B) SEM images of micropores in Strat-MTM
membrane after application of a 500 g mass onto microneedle rollers providing a downward force of 3.8 N (left), and micropores in Strat-MTM membrane after uni-
lateral manual rolling with the microneedle rollers (right). (C) OCT images showing the 500 and 750lm microneedle rollers [MN] penetrating the full thickness of
the Strat-MTM membrane [SM]. The 250 lm microneedles did not penetrate through the basal surface of the membrane. Artifacts are caused by the light casting
shadows beyond the microneedle tips.
946 A. OMOLU ET AL.
Figure 3. Effect of microneedle application on doxycycline permeation through Strat-MTM membrane (n¼ 4): (A) Cumulative concentration of doxycycline in recep-
tor compartment fluid after treatment with 250, 500 and 750 lm microneedle lengths. (B) Rate of drug permeation from linear regression of cumulative doxycycline
concentration during the hour-long lag period. Error bars represent the standard error of the mean. (C) SEM images of doxycycline crystals [DC] retained in and on
the Strat-MTM membrane shown occluding micropores [MP] in Strat-MTM membrane treated with 500lm rollers (left) and doxycycline crystal formation on the
membrane surface (right). (D) Box and whisker plots comparing the dry mass of membrane before microneedle permeation (‘before’) with the mass after the per-
meation study and post-desiccation (‘after’). ‘Control’ represents the membrane samples which had not been treated with rollers; ¼ p< .0001.
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activity, unlike FPCLs treated directly with doxycycline. There
was no statistically significant difference in gel contraction
between control FPCLs and FPCLs compartmentalized with
untreated Strat-MTM on any day; gel contraction values were
58.1 ± 2.1%, 79.7 ± 1.0%, 91.2 ± 0.7% and 92.8 ± 0.2% on days
1, 3, 6 and 7, respectively. There was also no statistically sig-
nificant difference in MMP activity between these two
groups. However, there was a statistically significant differ-
ence in both gel contraction and MMP activity between
FPCLs treated with doxycycline compartmentalized by Strat-
MTM and those treated directly with doxycycline on days 1, 3,
6 and 7 (Figure 4(C)).
Effect of microneedle application on transmembrane
doxycycline delivery to FPCLs
To investigate the effect of microneedle treatment on trans-
membrane permeation of doxycycline to FPCLs, the Strat-
MTM membrane was treated with microneedles of 250, 500
or 750lm in length and doxycycline solution applied to the
membrane’s apical surface. Treatment of the Strat-MTM with
the 250 lm microneedles resulted in a statistically significant
decrease in gel contraction compared with untreated
Strat-MTM on days 1 and 3 (p< .0001) but not on days 6 and
7 (Figure 4(E)). Increasing microneedle length resulted in sig-
nificantly reduced gel contraction for 500 lm (p< .001) and
750lm (p< .0001) microneedle-treated membranes com-
pared with untreated membranes on days 1, 3, 6 and 7.
There was also a significant difference in gel contraction
between 250 lm and 750 lm groups on day 7 (p< .001).
MMP activity was significantly reduced on day 7 for FPCLs
compartmentalized with 750 lm microneedle-treated
Strat-MTM (p< .01) (Figure 4(F)).
Discussion
Microneedles, typically ranging from 100 lm to 1mm in
length, sit at the interface between hypodermic needles and
transdermal patches (Nava-Arzaluz et al., 2012). They are con-
sidered an attractive, minimally invasive method of delivering
drugs across the tough SC and function to increase skin per-
meability by forming temporary channels that act as conduits
for drug transit. They are able to deliver a defined amount of
drug to a target skin layer and since they are able to deliver
drugs locally, can avoid distribution to the whole body via
systemic circulation, decreasing toxicity and reducing side
effects (Trommer & Neubert, 2006). Microneedles also have
improved patient compliance when compared with hypoder-
mic needles and have been shown to deliver drugs painlessly
and blood-free (Kaushik et al., 2001; Bal et al., 2008; Gupta
et al., 2011).
To achieve maximum clinical impact, microneedle-based
technologies need to be relatively low cost in comparison
with existing mechanical enhancer techniques. Microneedle
rollers are already commercially available for cosmetic appli-
cations but their utility for clinical purposes in chronic wound
treatment has not been explored to date. To investigate how
microneedle rollers facilitate delivery of doxycycline across
intact skin susceptible to chronic wounds, a novel dual
approach to in vitro modeling was devised. The recently
launched Strat-MTM membrane was used to asses both (i)
doxycycline permeation using a Franz diffusion cell system to
establish fundamental permeation data under infinite dose
conditions and (ii) the biological activity of the diffused drug
using a three-dimensional cell-enriched collagen matrix that
provided an indication of doxycycline-mediated inhibition of
MMP activity.
Micropore area and depth of penetration of the rollers
into Strat-MTM membrane correlated with microneedle
length. Since Strat-MTM was found to be impermeable to
doxycycline, micropores created by the microneedles acted
as the sole conduits for drug permeation. As a consequence,
the longer microneedles resulted in larger micropores and a
greater rate of doxycycline diffusion, with higher cumulative
concentrations of doxycycline in the receptor fluid. The rea-
sons for this are likely to be two-fold. Firstly, the longer
microneedles created micropores with a greater entry area
on the membranes apical surface. Secondly, they were also
able to penetrate through the entire 300lm thick Strat-MTM
membrane to a greater depth, creating a longer micropore
annulus into the target region than shorter microneedles
that did not fully penetrate the membrane. Previous studies
comparing the effect of different microneedle lengths have
also shown a correlation between increasing microneedle
length and increased drug permeation (Park et al., 2010; Kim
et al., 2012). In this study, it was observed that the maximum
length of the 500 lm and 750 lm microneedles did not
penetrate the membrane, since there was a residual portion
of their shafts that did not make contact with the mem-
brane’s apical surface. Possible explanations for this include
neighboring needles preventing maximum depth penetration
also referred to as the ‘bed of nails’ effect. Notably, micro-
pore closure and contraction of the skin in vivo is a biological
behavior that cannot be mimicked by the acellular Strat-MTM.
The resealing kinetics of micropores created by these micro-
needle rollers in human skin need to be investigated to give
an indication of the timeframe within which doxycycline
could be delivered intradermally, without the use of drug
delayers, during clinical application.
Rolling application of the microneedles resulted in larger
micropores compared with static impact insertion of the
microneedles using 3.8N of perpendicular force. Rolling
involves shearing forces that disrupt the membrane along the
y-axis that are not associated with perpendicular application
of force. The extent of membrane disruption by manual rolling
may be dependent on the number of rolls as well as the num-
ber of planes in which the microneedles are rolled in. In this
study, the microneedles were rolled unilaterally without
removal of the microneedles from the membrane; however,
other studies have used multilateral rolling which creates
overlapping micropores (Badran et al., 2009; You et al., 2010;
Zhou et al., 2010). This suggests that for ‘poke and patch’ IDD
and TDD, rolling is a more efficient way of permeabilizing skin
than static impact insertion of the microneedle system, and
that repeated rolls increase drug diffusion rates (Park et al.,
2010). However, the force applied with manual rolling in this
study, as well as in any proposed clinical application, is likely
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Figure 4. (A) Photographs of gel contraction in FPCLs treated with 416lM doxycycline and control FPCLs (n¼ 6). The collagen gels [CG] were cast into the plate’s
microwells [MW] on day 0 and photographed on days 1, 3, 6 and 7. Percentage gel contraction was calculated by measuring the area of the collagen gel relative to
the microwell. Control FPCLs, cultured in complete DMEM only, showed rapid contraction between days 1 and 3. Treatment of gels with 416 lM doxycycline signifi-
cantly reduced total percentage contraction by day 7 (p< .0001). (B) Percentage gel contraction was compared between control FPCLs (‘Control’), FPCLs compart-
mentalized from 416 lM doxycycline by the Strat-MTM membrane (‘Strat-MTM þDOX’) and FPCLs treated directly with 416 lM doxycycline (‘DOX’) (n¼ 6). Direct
treatment with doxycycline resulted in significantly reduced percentage gel contraction compared to control on all days. Strat-MTM was able to significantly inhibit
the delivery of 416 lM doxycycline to the FPCLs over the seven-day experiment by compartmentalizing the doxycycline. Due to this, no statistically significant dif-
ference in gel contraction was observed between the ‘Strat-MTM þDOX’ and ‘DOX’ groups. (C) Total MMP activity was compared between ‘Control’, ‘Strat-MTM
þDOX’ and ‘DOX’ groups (n¼ 6). In the ‘Control’ group, a significant increase in MMP activity was observed by days 3 and 7 compared to day 0. The ‘DOX’ group
exhibited significantly inhibited MMP activity compared to ‘Control’ on days 3 and 7 (p< .0001). The MMP activity for the ‘Strat-MTM þDOX’ groups showed no stat-
istically significant difference compared to ‘Control’ over the seven-day experiment but was significantly different to ‘DOX’ on days 3 and 7 (p< .0001). Error bars
represent the standard error of the mean (¼ p< .001, ¼ p< .0001). (D) Schematic representation of Strat-MTM membrane inserted into a cell crown and
mounted into an individual well of a 24-well glass-bottomed plate. The basal surface of the membrane was in contact with the DMEM immersing the FPCL.
Doxycycline solution was pipetted onto the apical surface of the membrane. (E) Percentage gel contraction was correlated with the length of the microneedles
used to permeabilize the Strat-MTM membrane to the 416lM doxycycline solution (n¼ 6). Permeabilization of the membrane to doxycycline using the microneedles
resulted in reduced gel contraction compared to control, significantly so for 250 lm on days 1 and 3, 500 lm on all days and 750 lm on all days assessed of the
seven-day experiment. The magnitude of effect was related to needle length; the 750 lm microneedle-treated membrane resulted in the greatest reduction in gel
contraction while the 250lm resulted in the least. (F) Correlation between MMP activity and Strat-MTM treated with increasing microneedle lengths (n¼ 6). A statis-
tically significant difference was observed only between untreated Strat-MTM and 750 lm microneedle-treated Strat-MTM on day 7. Error bars represent the standard
error of the mean (p< .01).
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to have been inconsistent due to intra- and interoperator vari-
ation. The impact of this, in terms of consistency of dose deliv-
ery, will require further investigation.
Previous studies have shown that doxycycline-mediated
inhibition of MMP activity in FPCL models results in reduced
gel contraction and MMP activity (Li et al., 2013). Therefore, a
similar system was used to verify biological activity of doxy-
cycline after its permeation through microneedle-treated
Strat-MTM. The concentration of doxycycline used in this
study (416 lM) matched the optimal concentration shown to
reduce fibroblast-mediated gel contraction of FPCLs (Franco
et al., 2006; Li et al., 2013). We firstly confirmed that the
effect of doxycycline on gel contraction inhibition was linked
to a decrease in MMP activity as previously shown (Li et al.,
2013), as total releasable MMP activity in the FPCL culture
medium was inhibited by 416lM doxycycline over a period
of seven days. When the Strat-MTM membrane was used to
mimic skin barrier function by compartmentalizing the FPCL
from the doxycycline treatment, it was able to effectively pre-
vent permeation of doxycycline to the underlying FPCL.
These findings corroborate the data from the Franz perme-
ation cell study which showed that no doxycycline was pre-
sent in the receptor fluid when untreated Strat-MTM was
placed into the Franz cell. When the microneedle rollers were
applied to the Strat-MTM, increasing lengths of the micronee-
dles on the roller directly correlated with the extent of Strat-
MTM permeabilization to doxycycline over a seven-day period
as assessed through reduced FPCL gel contraction and inhib-
ition of MMP activity.
A quantity of the doxycycline solution was retained as
crystals within and on the Strat-MTM membrane. These yellow
crystals were visible in hydrated membranes immediately
after the permeation study, confirming that their presence
was not a result of the drying process. They were also not
observed when PBS alone was delivered through the mem-
brane. The reason for the crystallization of doxycycline and
its deposition on the membrane is unclear; the donor fluid
concentration was a fifth of its solubility limit so, theoretic-
ally, the solution was unsaturated. Molecules in solution will
crystallize when a nucleation point is reached and it is more
energetically favorable to form and deposit crystals than
remain dissolved (Markov, 2003). Thus, it is possible that
there is an interaction between the Strat-MTM surface and
dissolved doxycycline molecules that stimulates this process.
The presence of these crystals explains why the theoretical
concentration of doxycycline in the receptor fluid was not
reached – crystallization of doxycycline inside micropores
would limit further drug permeation and also reduce the
amount of drug available to diffuse. A solvent, such as
methanol, could be used to improve doxycycline solubility in
the model. However, this is likely to interfere with the Strat-
MTM structure and integrity, confounding its true permeation
properties since it is structurally sensitive to such chemicals.
In in vivo human skin, drug crystallization needs to be
assessed and may be overcome through the addition of solu-
bilizing agents to the drug. Moreover, therapeutic concentra-
tions of doxycycline hyclate administered by IDD would in
reality be much lower than 10mg/ml, which was used to sat-
isfy infinite dose conditions.
There is great potential for the clinical application of
microneedle rollers in chronic wound management, specific-
ally to deliver the active drug in a timely manner to prevent
wound development and to treat existing tissue damage.
There are several ways this can be achieved. The microneedle
rollers could be used to permeabilize the surface of intact
skin overlying a very early stage wound, using their high
mobility and ability to cover large surface areas. A doxycyc-
line-infused patch or dressing could then be applied onto
the skin to promote wound healing. For early stage open
chronic wounds, the microneedle rollers could be used in a
circumferential manner, by rolling the device around the per-
imeter of the wound. This process should itself promote re-
epithelization, but also permeabilizes the surrounding skin to
the active drug in order to help reduce the spread of MMP-
mediated damage into the surrounding tissue (Liebl and
Kloth, 2012). For hygiene purposes, best clinical practice
would be single-use of the roller system given the nature of
the disease that the target patient population has, though
disinfection and sterilization would be possible for repeated
use on a single individual.
Conclusion
This study has demonstrated the potential utility of micro-
needle rollers as a facile and readily translatable technology
for IDD of doxycycline across intact skin at risk of chronic
wound formation. We have outlined the development of a
novel in vitro model of the human epidermis and dermis by
combining Strat-MTM membrane with the FPCL system. This
model is simple, economical and reproducible and provides a
good indication of how doxycycline treatment combined
with microneedle rollers may translate into in vivo experi-
ments using clinically relevant models that mimic chronic
wound microenvironments.
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